Silverarc Capital Management, LLC Biocryst Pharmaceuticals Inc Transaction History

Silverarc Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$4.98 - $6.77 $2.7 Million - $3.68 Million	-542,943 Reduced 68.58%	248,728 $1.49 Million
Q3 2023 Nov 13, 2023	BUY	$6.71 - $7.92 $206,446 - $243,674	30,767 Added 4.04%	791,671 $5.61 Million
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $1.27 Million - $1.61 Million	183,147 Added 31.7%	760,904 $5.36 Million
Q1 2023 May 15, 2023	BUY	$7.94 - $11.84 $2.43 Million - $3.62 Million	305,584 Added 112.28%	577,757 $4.82 Million
Q4 2022 Feb 14, 2023	BUY	$10.5 - $14.2 $898,485 - $1.22 Million	85,570 Added 45.86%	272,173 $3.12 Million
Q3 2022 Oct 28, 2022	BUY	$10.79 - $14.81 $1.44 Million - $1.97 Million	133,082 Added 248.65%	186,603 $2.35 Million
Q2 2022 Jul 25, 2022	SELL	$7.89 - $17.88 $385,852 - $874,403	-48,904 Reduced 47.75%	53,521 $566,000
Q1 2022 May 13, 2022	BUY	$11.56 - $19.76 $1.18 Million - $2.02 Million	102,425 New	102,425 $197,000
Q1 2021 May 18, 2021	SELL	$7.37 - $13.61 $810,700 - $1.5 Million	-110,000 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$3.37 - $8.61 $370,700 - $947,099	110,000 New	110,000 $820,000

279

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.